Veeva Link Key People alternative · for oncology biotech medical affairs not on the Vault platform
Veeva Link alternative: standalone oncology KOL intelligence without the Vault dependency
UNMIRI · See Literature Intelligence
Veeva Link Key People is the established KOL backbone for the Vault ecosystem: 85+ countries, 250k+ public sources, tight integration with Vault CRM and Vault Medical. As of early 2026, 13 of the top 20 biopharma have standardized on it enterprise-wide, with 95% renewal rates. If your organization is already on Vault, Link is the path of least resistance and this comparison page mostly tells you to stay on Link.
This page is for the biotechs that aren't. Specifically: precision-oncology medical affairs teams that don't have a Vault CRM contract, don't want to commit to the full ecosystem to get one product, and need biomarker-aware KOL ranking that Vault Link doesn't do.
At a glance
| Dimension | Veeva Link Key People | UNMIRI |
|---|---|---|
| Buying motion | Bundled with Vault CRM, Vault Medical, Vault PromoMats. Standalone deals are rare. | Standalone, API-first, no CRM dependency. Self-serve PLG entry, enterprise SaaS for larger teams. |
| Therapeutic-area scope | All therapy areas | Oncology-only, biomarker-stratified |
| KOL ranking signal | Aggregate scientific output, congress participation, payments, contributions to guidelines | Variant-conditioned: oncologists ranked by recent publications on specific gene+variant pairs |
| Coverage | Global, 85+ countries; 250k+ public sources, MLR-compliant data refresh | US-focused oncology, US-only data residency, daily refresh from open sources (PubMed, ClinicalTrials.gov, etc.) |
| Pricing | Enterprise, mid-six to seven figures annually; per-country / per-TA / per-seat pricing | $99/mo individual, $499/mo team, $25-75K enterprise |
| Deployment time | Months — bundled with Vault CRM rollout or contract negotiation | Same-week trial, weeks to enterprise rollout |
| Renewal rate / adoption | 95% renewal, 13 of top 20 biopharma standardized | Pre-pilot. Honest about stage. PLG self-serve removes commitment friction. |
Buying motion is the real wedge
Veeva Link wins on data depth, global coverage, and the gravitational pull of the Vault ecosystem. For biopharma already in that orbit, this comparison page exists mostly to tell you to stay there.
For everyone else — particularly precision-oncology biotechs not on Vault — the buying motion is the real wedge. Veeva Link standalone deals are rare, and pricing reflects the bundling assumption. UNMIRI Engine 3 is API-first, no CRM dependency, deployable in days at $99-$499/mo individual or team tiers, with biomarker-aware ranking that Vault Link doesn't do natively. Different shape, different price point, different commitment.
When Veeva Link Key People is the right pick
- You're on Veeva Vault CRM and a Link Key People contract is part of the bundle. The buying motion is already done.
- You need global KOL coverage across all therapy areas — Veeva's 85+ country footprint and Vault's enterprise MLR workflow are non-negotiable for global biopharma.
- You're a top-20 biopharma with 6-9 month enterprise procurement cycles and a dedicated Vault implementation team.
- Your medical affairs workflow lives in Vault Medical and you need the data layer to be Veeva-native.
When UNMIRI is the right pick
- You're not on the Veeva Vault stack and you don't want to commit to it to get one product (KOL data).
- You're a 50-500 person oncology biotech where Vault CRM hasn't been adopted and Link's $XXX-figure entry price is way above your medical affairs budget.
- You need biomarker-conditioned KOL ranking. Vault Link can rank oncology KOLs by publication volume; it can't easily rank them by KRAS G12C publication volume specifically.
- Your team wants to try the product in 14 days, not negotiate it for two quarters.
- Your business case is precision-oncology-specific and you'd rather have oncology-deep than all-therapy-area-broad.
Frequently asked questions
- Can UNMIRI integrate with Vault?
- Not natively today. UNMIRI Engine 3 has FHIR / API output. If your team is on Vault and you want UNMIRI's oncology + biomarker layer to flow into Vault Medical, that's a custom integration. For 50-500 person biotechs not already on Vault, this is rarely the deciding factor.
- What about MLR compliance?
- UNMIRI's output is deterministic-template-rendered with reproducibility snapshots — every digest can be regenerated identically months later. That's the MLR-defensibility argument. Vault Link's data refresh cadence and integrations with Vault PromoMats are mature and harder for a newer entrant to match. If MLR-workflow integration with Vault PromoMats is non-negotiable, Veeva wins; if it's optional, UNMIRI is the lighter-weight alternative.
- Why not target enterprise directly?
- We will, when revenue justifies the sales motion. Today, the wedge is the segment Veeva can't economically reach — biotechs without Vault, 50-500 employees, oncology-focused. That's also the segment where Veeva's enterprise procurement assumption breaks down.
- Does UNMIRI cover global KOLs?
- US-focused today, with US-only data residency. If your medical affairs work spans EU, Japan, China, or LATAM, Veeva Link's coverage is genuinely broader. UNMIRI's expansion plan depends on customer demand and data-residency requirements in each region.
See if standalone fits
14-day trial, no credit card. If your oncology medical affairs work isn't embedded in a Vault ecosystem, see what biomarker-aware KOL ranking looks like.